Clinical guidelines and off-license recombinant activated factor VII: Content, use, and association with patient outcomes

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 12, 2009, Pages 2016-2022

  Willis, C D ^a   Cameron, P A ^a   Phillips, L E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Factor VIIa; Guidelines; Hemostasis; NovoSeven

Indexed keywords

BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; AUSTRALIA; HEMOPHILIA A; HOSPITAL; HUMAN; MORTALITY; NEW ZEALAND; PRACTICE GUIDELINE; REGISTER; STANDARD; STATISTICS; TREATMENT OUTCOME;

AUSTRALIA; FACTOR VIIA; GUIDELINE ADHERENCE; HEMOPHILIA A; HOSPITALS; HUMANS; MORTALITY; NEW ZEALAND; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS; REGISTRIES; TREATMENT OUTCOME;

EID: 77449107572     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03632.x     Document Type: Article

References (30)

1. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
2. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
3. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-18.
4. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
5. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S61-5.
6. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
7. Karkouti K, Beattie WS, Wijeysundera DN, Yau TM, McCluskey SA, Ghannam M, Sutton D, Van Rensburg A, Karski J. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45: 26-34.
8. Lodge JPA, Jonas S, Jones R, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasas J, McAlister V, Mirza D. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-9.
9. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol 2007; 114: 8-15.
10. European Medicines Agency (EMEA). European Public Assessment Report: NovoSeven. EMEA/264577/2009. London: EMEA/H/C/74, 2009.
11. Tabarrok A. From off-label prescribing towards a new FDA. Med Hypotheses 2009; 72: 11-13.
12. Hsia CC, Zurawska JH, Tong MZY, Eckert K, McAlister VC, Chin-Yee IH. Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfus Med 2009; 19: 43-9.
13. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
14. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-37.
15. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325-31.
16. Vincent J-L, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Critical Care 2006; 10: R120.
17. Welsh A, McLintock C, Gatt S, Somerset D, Popham P, Ogle R. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust NZ J Obstet Gynaecol 2008; 48: 12-16.
18. Rudisill C, Hockman R, Degregory K, Mutnick A, Macik B. Implementing guidelines for the institutional use of factor VIIa (recombinant): a multidisciplinary solution. Am J Health Syst Pharm 2006; 63: 1641-6.
19. Karkouti K, Yau TM, Van Rensburg A, McCluskey SA, Callum J, Wijeysundera DN, Beattie WS. The effects of a treatment protocol for cardiac surgical patients with excessive blood loss on clinical outcomes. Vox Sang 2006; 91: 148-56.
20. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317-22.
21. Keffer JH. Guidelines and algorithms: perceptions of why and when they are successful and how to improve them. Clin Chem 2001; 47: 1563-72.
22. Price J, Ekleberry A, Grover A, Melendy S, Baddam K, McMahon J, Villalba M, Johnson M, Zervos MJ. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med 1999; 27: 2118-24.
23. Stover EP, Siegel LC, Parks R, Body SC, Maddi R, D'Ambra MN, Mangano DT, Levin J, Spiess BD. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology 1998; 88: 327-33.
24. Nuttall GA, Oliver WC, Santrach PJ, Bryant S, Dearani JA, Schaff HV, Ereth MH. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001; 94: 773-81.
25. Goodnough LT, Despotis GJ. Future directions in utilization review: the role of transfusion algorithms. Transfus Apher Sci 1998; 19: 97-105.
26. Despotis GJ, Goodnough LT. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg 2000; 70: S20-32.
27. Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2008; 38: 156-65.
28. Owen P, Golightly L, MacLaren R, Ferretti K, Badesch D. Formulary management of recombinant factor VIIa at an academic medical center. Ann Pharmacother 2008; 42: 771-6.
29. Sinuff T, Cook D, Giacomini M, Heyland D, Dodek P. Facilitating clinician adherence to guidelines in the intensive care unit: a multicenter, qualitative study. Crit Care Med 2007; 35: 2083-9.
30. Ricart M, Lorente C, Diaz E, Kollef M, Rello J. Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia. Crit Care Med 2003; 31: 2693-6.